Literature DB >> 17498668

Artemisinin effectiveness in erythrocytes is reduced by heme and heme-containing proteins.

Napawan Ponmee1, Tatsanee Chuchue, Prapon Wilairat, Yongyuth Yuthavong, Sumalee Kamchonwongpaisan.   

Abstract

Artemisinin loses its antimalarial activity on prolonged exposure to erythrocytes, especially alpha-thalassemic erythrocytes. In this report, we show that the major artemisinin-inactivating factor in cytosol of normal erythrocytes was heat-labile but a heat-stable factor from alpha-thalassemic cells also played a significant role in reducing artemisinin effectiveness, which was shown to be heme released from hemoglobin (Hb). Studies of fractionated lysate from genetically normal erythrocytes revealed that the protein fraction with molecular weight greater than 100 kDa was capable of reducing artemisinin effectiveness more readily than lower molecular weight fraction. Catalase and Hb A, but not selenoprotein glutathione peroxidase, were capable of reducing artemisinin effectiveness. Hemin (ferriprotoporphyrin IX) also reduced artemisinin effectiveness in a concentration- and time-dependent manner. It is concluded that heme and heme-containing proteins in erythrocyte are largely responsible for reducing artemisinin effectiveness and may contribute to resistance of Plasmodium falciparum infecting alpha-thalassemic erythrocytes observed in vitro.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498668      PMCID: PMC1949810          DOI: 10.1016/j.bcp.2007.03.008

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  30 in total

Review 1.  An overview of chemotherapeutic targets for antimalarial drug discovery.

Authors:  P L Olliaro; Y Yuthavong
Journal:  Pharmacol Ther       Date:  1999-02       Impact factor: 12.310

2.  Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX.

Authors:  S Paitayatat; B Tarnchompoo; Y Thebtaranonth; Y Yuthavong
Journal:  J Med Chem       Date:  1997-02-28       Impact factor: 7.446

Review 3.  Oxidative denaturation of red blood cells in thalassemia.

Authors:  E Shinar; E A Rachmilewitz
Journal:  Semin Hematol       Date:  1990-01       Impact factor: 3.851

4.  Binding of dihydroartemisinin to hemoglobin H: role in drug accumulation and host-induced antimalarial ineffectiveness of alpha-thalassemic erythrocytes.

Authors:  P Vattanaviboon; P Wilairat; Y Yuthavong
Journal:  Mol Pharmacol       Date:  1998-03       Impact factor: 4.436

Review 5.  Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy.

Authors:  S R Meshnick; T E Taylor; S Kamchonwongpaisan
Journal:  Microbiol Rev       Date:  1996-06

6.  The interaction of artemisinin with malarial hemozoin.

Authors:  Y L Hong; Y Z Yang; S R Meshnick
Journal:  Mol Biochem Parasitol       Date:  1994-01       Impact factor: 1.759

Review 7.  Thalassemia: pathophysiology of red cell changes.

Authors:  S L Schrier
Journal:  Annu Rev Med       Date:  1994       Impact factor: 13.739

8.  Reaction of antimalarial endoperoxides with specific parasite proteins.

Authors:  W Asawamahasakda; I Ittarat; Y M Pu; H Ziffer; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

9.  tBOOH acts as a suicide substrate for catalase.

Authors:  H Pichorner; G Jessner; R Ebermann
Journal:  Arch Biochem Biophys       Date:  1993-01       Impact factor: 4.013

10.  Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes.

Authors:  S Kamchonwongpaisan; G Chandra-ngam; M A Avery; Y Yuthavong
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

View more
  8 in total

Review 1.  Plasmodium drug targets outside the genetic control of the parasite.

Authors:  David J Sullivan
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

2.  Exploiting structural analysis, in silico screening, and serendipity to identify novel inhibitors of drug-resistant falciparum malaria.

Authors:  Tina Dasgupta; Penchit Chitnumsub; Sumalee Kamchonwongpaisan; Cherdsak Maneeruttanarungroj; Sara E Nichols; Theresa M Lyons; Julian Tirado-Rives; William L Jorgensen; Yongyuth Yuthavong; Karen S Anderson
Journal:  ACS Chem Biol       Date:  2009-01-16       Impact factor: 5.100

3.  Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.

Authors:  Sri Riyati Sugiarto; Brioni R Moore; Julie Makani; Timothy M E Davis
Journal:  Clin Infect Dis       Date:  2018-02-10       Impact factor: 9.079

4.  Stability of peroxide antimalarials in the presence of human hemoglobin.

Authors:  Darren J Creek; Eileen Ryan; William N Charman; Francis C K Chiu; Richard J Prankerd; Jonathan L Vennerstrom; Susan A Charman
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

5.  Two distinct and competitive pathways confer the cellcidal actions of artemisinins.

Authors:  Chen Sun; Jian Li; Yu Cao; Gongbo Long; Bing Zhou
Journal:  Microb Cell       Date:  2015-01-02

Review 6.  The molecular and cellular action properties of artemisinins: what has yeast told us?

Authors:  Chen Sun; Bing Zhou
Journal:  Microb Cell       Date:  2016-04-14

7.  Plasmodium parasites mount an arrest response to dihydroartemisinin, as revealed by whole transcriptome shotgun sequencing (RNA-seq) and microarray study.

Authors:  Philip J Shaw; Sastra Chaotheing; Pavita Kaewprommal; Jittima Piriyapongsa; Chayaphat Wongsombat; Nattida Suwannakitti; Pongpisid Koonyosying; Chairat Uthaipibull; Yongyuth Yuthavong; Sumalee Kamchonwongpaisan
Journal:  BMC Genomics       Date:  2015-10-21       Impact factor: 3.969

8.  The Antagonizing Role of Heme in the Antimalarial Function of Artemisinin: Elevating Intracellular Free Heme Negatively Impacts Artemisinin Activity in Plasmodium falciparum.

Authors:  Pan Zhu; Bing Zhou
Journal:  Molecules       Date:  2022-03-08       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.